Inventor
SUN JEONGHOON
US39 patents
⚠️ This page may combine multiple inventors who share the name “SUN JEONGHOON”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
AMGEN INC
18 patentsUS8034770B2Oct 11, 2011
FGF21 polypeptides comprising two or more mutations
AMGEN INC63 citations99
US8361963B2Jan 29, 2013
Uses of FGF21 polypeptides comprising two or more mutations
AMGEN INC64 citations98
US8999917B2Apr 7, 2015
Variant activin receptor polypeptides and uses thereof
AMGEN INC48 citations97
US7947646B2May 24, 2011
Variant activin receptor polypeptides
AMGEN INC66 citations97
US9809638B2Nov 7, 2017
Variant activin receptor
AMGEN INC25 citations94
US9273106B2Mar 1, 2016
FGF mutants with reduced proteolysis and aggregation
AMGEN INC9 citations92
US11072640B2Jul 27, 2021
Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
AMGEN INC3 citations84
US10407487B2Sep 10, 2019
Variant activin receptor
AMGEN INC11 citations84
US10011642B2Jul 3, 2018
Methods of treating of diabetes and obesity using FGF21 mutants
AMGEN INC4 citations84
US9493530B2Nov 15, 2016
FGF21 mutants comprising a mutation at position 98, 171 and/or 180
AMGEN INC10 citations84
US9447165B2Sep 20, 2016
Variant activin IIB receptor
AMGEN INC11 citations84
US10308704B2Jun 4, 2019
Isolated nucleic acid molecules encoding stabilized receptor polypeptides and uses thereof
AMGEN INC12 citations83
US9610327B2Apr 4, 2017
Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
AMGEN INC11 citations83
US9688756B2Jun 27, 2017
Variant Fc-polypeptides with enhanced binding to the neonatal Fc receptor
AMGEN INC3 citations68
US11840558B2Dec 12, 2023
Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
AMGEN INC0 citations62
US11685770B2Jun 27, 2023
Stabilized receptor polypeptides and uses thereof
AMGEN INC0 citations62
US7981425B2Jul 19, 2011
Thrombopoietic compounds
AMGEN INC2 citations61
US10189890B2Jan 29, 2019
Variants of tissue inhibitor of metalloproteinase type three (TIMP-3), compositions and methods
AMGEN INC0 citations50
CELGENE CORP
7 patentsUS10428145B2Oct 1, 2019
PD-1 binding proteins and methods of use thereof
CELGENE CORP10 citations77
US12545740B2Feb 10, 2026
Engineering of an antibody for tumor-selective binding of CD47
CELGENE CORP0 citations56
US12428488B2Sep 30, 2025
Engineering of an antibody for tumor-selective binding of CD47
CELGENE CORP0 citations56
US11427632B2Aug 30, 2022
Antibodies with low immunogenicity and uses thereof
CELGENE CORP0 citations56
US12084499B2Sep 10, 2024
SIRP-α binding proteins and methods of use thereof
CELGENE CORP0 citations51
US11591390B2Feb 28, 2023
SIRP-α binding proteins and methods of use thereof
CELGENE CORP0 citations51
US11401336B2Aug 2, 2022
BCMA-binding antibodies and uses thereof
CELGENE CORP0 citations45
BELOUSKI EDWARD JOHN
6 patentsUS8835385B2Sep 16, 2014
FGF21 polypeptides comprising two or more mutations and uses thereof
BELOUSKI EDWARD JOHN48 citations97
US8795985B2Aug 5, 2014
FGF 21 polypeptides comprising two or more mutations and uses thereof
BELOUSKI EDWARD JOHN48 citations97
US8642546B2Feb 4, 2014
FGF21 mutant fusion polypeptides and uses thereof
BELOUSKI EDWARD JOHN64 citations97
US8618053B2Dec 31, 2013
FGF21 mutants multimers and uses thereof
BELOUSKI EDWARD JOHN45 citations97
US8410051B2Apr 2, 2013
FGF21 mutants and uses thereof
BELOUSKI EDWARD JOHN63 citations97
US8188040B2May 29, 2012
FGF21 mutants and uses thereof
BELOUSKI EDWARD JOHN59 citations97
SUN JEONGHOON
3 patentsUS8716459B2May 6, 2014
Isolated nucleic acid molecules encoding variant activin receptor polypeptides
SUN JEONGHOON48 citations96
US8410043B2Apr 2, 2013
Stabilized activin IIB receptor polypeptides and uses thereof
SUN JEONGHOON54 citations96
US8501678B2Aug 6, 2013
Variant activin receptor polypeptides and uses thereof
SUN JEONGHOON38 citations93